BioSpace News Archive

Business

Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China

Zai Lab granted license to commercialize oncology platform technology Tumor Treating Fields, including the brand name Optune®, in China, Hong Kong, Macau and Taiwan

September 12, 2018
·
8 min read
Policy

U.S. Department of Defense Awards $3.3 Million Grant to Alivio Therapeutics

Research award will support preclinical activities to advance product candidate for the treatment of interstitial cystitis/bladder pain syndrome into the clinic

September 12, 2018
·
6 min read
Policy

Biohaven Announces Submission of IND for BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist for the Treatment of Migraine

BHV-3500 is the first intranasal formulation of a small molecule calcitonin gene-related peptide receptor antagonist to be advanced for human dosing in clinical trials.

September 12, 2018
·
7 min read
Pharm Country

Exude Launches a New Benefits Product

Exude, Inc. expands its employee benefit offerings through a new program, Exude Solution Builder.

September 12, 2018
·
1 min read
Deals

Shore Capital Partners Announces Acquisition of Eagle Laboratories

Shore Capital Partners, LLC (“Shore Capital” or “Shore”) is pleased to announce that Innovia Medical (“Innovia”), its specialty surgical products platform, has partnered with Eagle Laboratories (“Eagle Labs”).

September 12, 2018
·
3 min read
Job Trends

Systems Oncology Announces the ExpansiveAI Project to Advance Artificial Intelligence Capable of Imagination

Dr. Spyro Mousses, CEO of Systems Oncology, LLC, announced the launch of the ExpansiveAI project today at the AIMed Conference in London, UK

September 12, 2018
·
2 min read
Beyond the prize - new customized reward program gets personal

For many Canadians, life is a balancing act. Between a full-time job, family commitments and social obligations, finding time to care for your financial, physical and mental health can be tough.

September 12, 2018
·
3 min read
Can-Fite to Present the Anti-Fibrogenic Effects of Namodenoson at the Hepatic Fibrosis Conference of the American Association for the Study of Liver Diseases (AASLD)

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, today announced its poster presentation of the anti-fibrogenic effects of Namodenosen in NAFLD/NASH pre-clinical data at the Hepatic Fibrosis Single Topic Conference of the American Association for the Study of Liver Diseases

September 12, 2018
·
5 min read
FDA

Amneal Announces FDA Approval and Launch of Generic Chlorpromazine Hydrochloride Tablets USP and Approval of Methylergonovine Maleate Tablets USP

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced it has received U.S. Food and Drug Administration (FDA) approval on its Abbreviated New Drug Application (ANDA) for Chlorpromazine Hydrochloride Tablets USP,

September 12, 2018
·
7 min read
Concordia International Corp. Provides Further Update On Its Recently Completed Recapitalization Transaction and the Issue Price of its Private Placement

Concordia’s US$586.5 million private placement (the “Private Placement”) for new limited voting shares of Concordia, at a price of US$13.69 per limited voting share and representing in the aggregate approximately 87.69% of the outstanding limited voting shares of Concordia

September 12, 2018
·
4 min read